|Sociedad Anónima (Mercado Continuo: ALM-MC: ALM)|
|Founder||Antonio Gallardo Carreras|
|Headquarters||Ronda del General Mitre, 151
|Products||Ebastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, Actikerall.|
|Revenue||€859.3 million (2016)|
Number of employees
|more than 1,900(2016) |
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and United States.
1943 Foundation of Laboratorios Almirall SA.
1979 Launch of the gastroprokinetic clebopride in Spain, the first product from the company’s internal research to obtain a license in another country.
1984 Launch of the antacid almagate in Spain.
1992 Launch of the anti-inflammatory aceclofenac in Spain.
1993 Opening of the affiliate in Portugal.
1994 Opening of the new headquarters of Almirall in Barcelona.
1997 Merger of Almirall and Prodesfarma.
2001 Opening of the affiliate in Mexico and acquisition of the French affiliate.
2002 Opening of the affiliate in Italy.
2003 Opening of the affiliate in Germany.
2007 Stock market flotation and trading on the continuous market in Spain. Acquisition of Hermal, European company specialized in dermatology, from Reckitt Benckiser. Acquisition of a portfolio of eight products from Shire plc.
2008 Opening of affiliates in Austria, Poland, United Kingdom-Ireland and Switzerland.
2010 Opening of affiliate in the Nordic Countries.
2011 Almirall launches Actikerall prescribed for the local treatment of actinic keratosis.
2012 Opening of the affiliate in Canada. Launch of aclidinium, prescribed for chronic obstructive pulmonary disease (COPD), in Europe under the brand Eklira Genuair and Bretaris Genuair and in the United States under the brand Tudorza Pressair. Launch of Monovo for the treatment of inflammatory skin diseases such as psoriasis.
2013 Acquisition of Aqua Pharmaceuticals, the USA company specialized in dermatology. Launch of linaclotide in Europe (Constella) for irritable bowel syndrome with constipation (IBS-C) and Opening of an affiliate in the Netherlands.
2014 Almirall transfers the rights of its respiratory franchise to Astrazeneca to thereby focus on the Dermatology area.
2015 Almirall declares its strategic intention to become a leading pharmaceutical company in the field of Dermatology worldwide and continues with its expansion by acquiring Poli Group Holding.
2016 Almirall acquires ThermiGen LLC.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
The company has three R&D centres distributed in Spain and Germany (Reinbek) and Switzerland (Lugano). The R&D centre in Sant Feliu de Llobregat (Barcelona), houses the departments involved in all stages of R&D, as well as the development of new chemical entities. The Reinbek Centre of Excellence for Dermatology specializes in the development of new formulas for the treatment of skin diseases.
The company also has three production centres: two in Spain, the pharmaceutical plant in Sant Andreu de la Barca (Barcelona) and the pharmaceutical and chemical plant in Sant Celoni (Barcelona); and a pharmaceutical plant in Germany (Reinbek); as well as 13 affiliates in Germany, Austria, Belgium-Luxembourg, the United States, France, the Netherlands, Italy, the Nordic Countries, Poland, Portugal, the United Kingdom-Ireland, Spain and Switzerland.
|2010||2011||2012||2013||2014 ||2015 ||2016 |
|Total revenue||€ 1002,1 MM||€ 873,1 MM||€ 900,2 MM||€ 825,5 MM||€ 1.407,4 MM||€ 769 MM||€ 859,3 MM|
|Net sales||€882.4 MM||€768.4 MM||€682.9 MM||€692.9 MM||€786.4 MM||€685 MM||€764,4 MM|
|% International sales||-||50%||60%||62%||70%||68%||70%|
|% Sales of own medicines||-||-||59%||64%||70%||67%||77%|
|Investment in R&D ||16.4% of net sales||18.8% of net sales||23.4% of net sales||18% of net sales||12.8% of net sales||9.7% of net sales||12,9% of net sales|
|R&D Centres ||3||3||3||3||2||2||3|
|Acticlate||Doxycycline hyclate||Severe Acne|
|Tesavel and Efficib||Sitagliptin and sitagliptin/metformin||Diabetes|
|Solaraze||Diclofenac sodium||Actinic keratosis|
|Cordran||Fludroxycortide||Inflammation and itching of the skin|
|Cleboril||Clebopride||Gastroesophageal reflux disease|
|Actikerall||5-Fluorouracil / salicylic acid||Actinic keratosis|
|Sativex||Nabiximols||Spasticity in Multiple Sclerosis|
- Products «Products of Almirall S.A.» Retrieved 17th December 2014
- Financial Results 2016
- Company Overview
- Almirall «History» Retrieved 18 December 2014
- Almirall: financial data 2016
- Almirall «What is the size of Almirall's overall workforce?» Retrieved 30 July 2014
- Almirall: financial data 2014
- Almirall: financial data 2015
- Almirall: financial data 2016
- Partnering and Collaboration «Partnering and Collaboration» Retrieved 18 December 2014
- R&D in Key Therapeutic Areas «R&D in Key Therapeutic Areas» Retrieved 18 December 2014